Research
Hormonal
49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.
Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.
StrongSupportsmedium confidence
A full stomach was observed in 21/43 (49%) of patients receiving semaglutide treatment compared with 8/44 (18%) of controls.
Why this rating
Based on a prospective, multicentre, matched case-control study design.
Source
Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study
Nils Vlaeminck et al. · Anaesthesia · 2026
DOI 10.1111/anae.70129
cohort · n=88Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →